Michael J. Farrell - Nov 7, 2025 Form 4 Insider Report for RESMED INC (RMD)

Signature
Michael J. Farrell, Chairman and CEO
Stock symbol
RMD
Transactions as of
Nov 7, 2025
Transactions value $
-$1,186,535
Form type
4
Date filed
11/10/2025, 07:07 PM
Previous filing
Oct 9, 2025
Next filing
Nov 13, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Farrell Michael J. Chairman and CEO, Director RESMED INC., 9001 SPECTRUM CENTER BLVD, SAN DIEGO Michael J. Farrell, Chairman and CEO 2025-11-10 0001485164

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $99.9K +983 +0.21% $101.64 469K Nov 7, 2025 Direct F1, F2
transaction RMD ResMed Common Stock Options Exercise $714K +7.03K +1.5% $101.64 476K Nov 7, 2025 Direct F1
transaction RMD ResMed Common Stock Sale -$2M -8.01K -1.68% $249.75 468K Nov 7, 2025 Direct F1, F3
holding RMD ResMed Common Stock 2.09K Nov 7, 2025 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -983 -12.27% $0.00 7.03K Nov 7, 2025 ResMed Common Stock 983 $101.64 Direct F1, F4
transaction RMD ResMed Common Stock Options Options Exercise $0 -7.03K -100% $0.00 0 Nov 7, 2025 ResMed Common Stock 7.03K $101.64 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2 Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.
F3 This transaction was executed in multiple trades at prices ranging from $248.13 - $251.46. The price reported above reflects the weighted average sale price.
F4 Represents date options first become exercisable. Options vest 1/3 per year.